Xuemei Huang, MD
Neurology · Charlottesville, VANPI 1619048956
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Acorda Therapeutics, Inc accounts for 60.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for neurology clinicians in VA, where the typical reported total is $1,288.
Across 2 payments — averaging $74.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acorda Therapeutics, Inc$90
- Boston Scientific$59
Across 71 payments — averaging $5777.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$164K
- Pfizer$113K
- Biohaven Pharmaceuticals, Inc.$79K
- H. Lundbeck A S$29K
- Biohaven Pharmaceutical Holding Company Ltd.$25K
- Teva Pharmaceuticals USA, Inc.$227
What the payments were for
- Food & beverage$149100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acorda Therapeutics, Inc | 1 | $90 |
| Boston Scientific | 1 | $59 |
How this compares
$149 in reported general payments places this provider in the 20th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 44 | $66,638 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 89 | $7,110 |
| Selegiline Hcl | 56 | $6,501 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 163 | $6,325 |
| Rasagiline Mesylate | 30 | $4,383 |
| Rivastigmine | 18 | $2,542 |
| AmantadineAmantadine Hcl | 42 | $2,423 |
| Fludrocortisone Acetate | 18 | $651 |
| Donepezil Hcl | 53 | $520 |
| Quetiapine Fumarate | 22 | $498 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 17 | $373 |
| Gabapentin | 21 | $219 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other neurology in Charlottesville
- Robert ShinCharlottesville$1.7M
- Brian WeinshenkerCharlottesville$195K
- Robert SawyerCharlottesville$55K
- Nathan FountainCharlottesville$45K
- Helen Dainton-HowardCharlottesville$41K
- Alissa HiginbothamCharlottesville$37K
- Ramsey FalconerAlexandria$2M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.